Generation of a syngeneic mouse model to study the intraperitoneal dissemination of ovarian cancer with in vivo luciferase imaging

Luminescence

Volumn 24, Issue 5, 2009, Pages 324-331

  Toyoshimaa, Masafumi ^a   Tanaka, Yoshinori ^a   Matumoto, Mitsuyo ^a   Yamazaki, Miyuki ^a   Nagase, Satoru ^a   Sugamura, Kazuo ^a   Yaegashi, Nobuo ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

HM 1; In vivo imaging; Intraperitoneal dissemination; Ovarian cancer; Syngeneic mouse model

Indexed keywords

BIOLUMINESCENCE; CELL CULTURE; DISEASE CONTROL; DISEASES; MAMMALS; PHYSIOLOGICAL MODELS; TUMORS;

ANTI-CANCER THERAPEUTICS; HM-1; IN-VIVO; IN-VIVO IMAGING; INTRAPERITONEAL; INTRAPERITONEAL DISSEMINATION; MICE MODELS; OVARIAN CANCERS; PHYSIOLOGICAL CONDITION; SYNGENIC MOUSE MODEL;

CELLS;

MUS;

EID: 70350376357     PISSN: 15227235     EISSN: 15227243     Source Type: Journal    
DOI: 10.1002/bio.1112     Document Type: Article

References (41)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics, 2006. CA Cancer J. Clin. 2006; 56: 106-130.
2. Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat. Rev. Cancer 2003; 3: 502-516.
3. Shaw TJ, Senterman MK, Dawson K, Crane CA, Vanderhyden BC. Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. Mol. Ther. 2004; 10: 1032-1042.
4. Greenaway J, Moorehead R, Shaw P, Petrik J. Epithelial-stromal interaction increases cell proliferation, survival and tumorigenicity in a mouse model of human epithelial ovarian cancer. Gynecol. Oncol. 2008; 108: 385-394.
5. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006; 124: 263-266.
6. Roby KF, Taylor CC, Sweetwood JP, et al. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis 2000; 21: 585-591.
7. Roberts PC, Mottillo EP, Baxa AC et al. Sequential molecular and cellular events during neoplastic progression: a mouse syngeneic ovarian cancer model. Neoplasia 2005; 7: 944-956.
8. Zhang L, Yang N, Garcia JR et al. Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma. Am. J. Pathol. 2002; 161: 2295-2309.
9. Tseng JC, Hurtado A, Yee H et al. Using sindbis viral vectors for specific detection and suppression of advanced ovarian cancer in animal models. Cancer Res. 2004; 64: 6684-6692.
10. Said N, Socha MJ, Olearczyk JJ, et al. Normalization of the ovarian cancer microenvironment by SPARC. Mol. Cancer Res. 2007; 5: 1015-1030.
11. Hashimoto M, Niwa O, Nitta Y, Takeichi M, Yokoro K. Unstable expression of E-cadherin adhesion molecules in metastatic ovarian tumor cells. Jpn. J. Cancer Res. 1989; 80: 459-463.
12. Kiguchi K, Kubota T, Aoki D, et al. A patient-like orthotopic implantation nude mouse model of highly metastatic human ovarian cancer. Clin. Exp. Metastasis 1998; 16: 751-756.
13. Nilsson EE, Westfall SD, McDonald C, et al. An in vivo mouse reporter gene (human secreted alkaline phosphatase) model to monitor ovarian tumor growth and response to therapeutics. Cancer Chemother. Pharmacol. 2002; 49: 93-100.
14. Kraeber-Bodere F, Mishra A, Thedrez P, et al. Pharmacokinetics and biodistribution of samarium-153-labelled OC125 antibody coupled to CITCDTPA in a xenograft model of ovarian cancer. Eur. J. Nucl. Med. 1996; 23: 560-567.
15. Burbridge MF, Kraus-Berthier L, Naze M, et al. Biological and pharmacological characterisation of three models of human ovarian carcinoma established in nude mice: use of the CA125 tumour marker to predict antitumour activity. Int. J. Oncol. 1999; 15: 1155-1162.
16. Anker P, Lyautey J, Lederrey C, Stroun M. Circulating nucleic acids in plasma or serum. Clin. Chim. Acta 2001; 313: 143-146.
17. Lui YY, Dennis YM. Circulating DNA in plasma and serum: biology, preanalytical issues and diagnostic applications. Clin. Chem. Lab. Med. 2002; 40: 962-968.
18. Gossmann A, Helbich TH, Mesiano S, et al. Magnetic resonance imaging in an experimental model of human ovarian cancer demonstrating altered microvascular permeability after inhibition of vascular endothelial growth factor. Am. J. Obstet. Gynecol. 2000; 183: 956-963.
19. Chaudhuri TR, Mountz JM, Rogers BE, Partridge EE, and Zinn KR. Light-based imaging of green fluorescent protein-positive ovarian cancer xenografts during therapy. Gynecol. Oncol. 2001; 82: 581-589.
20. McElroy W. Properties of the reaction utilizing adenosinetriphosphate for bioluminescence. J. Biol. Chem. 1951; 191: 547-557.
21. Caceres G, Zankina R, Zhu X, et al. Determination of chemotherapeutic activity in vivo by luminescent imaging of luciferase-transfected human tumors. Anticancer Drugs 2003; 14: 569-574.
22. Jenkins DE, Oei Y, Hornig YS, et al. Bioluminescent imaging (BLI) to improve and refine traditional murine models of tumor growth and metastasis. Clin. Exp. Metastasis 2003; 20: 733-744.
23. Scatena CD, Hepner MA, Oei YA, et al. Imaging of bioluminescent LNCaP-luc-M6 tumors: a new animal model for the study of metastatic human prostate cancer. Prostate 2004; 59: 292-303.
24. Zeamari S, Rumping G, Floot B, Lyons S, Stewart FA. In vivo bioluminescence imaging of locally disseminated colon carcinoma in rats. Br. J. Cancer 2004; 90: 1259-1264.
25. Szentirmai O, Baker CH, Lin N, et al. Noninvasive bioluminescence imaging of luciferase expressing intracranial U87 xenografts: correlation with magnetic resonance imaging determined tumor volume and longitudinal use in assessing tumor growth and antiangiogenic treatment effect. Neurosurgery 2006; 58: 365-372; discussion 372.
26. Zeng L, Kizaka-Kondoh S, Itasaka S, et al. Hypoxia inducible factor-1 influences sensitivity to paclitaxel of human lung cancer cell lines under normoxic conditions. Cancer Sci. 2007; 98: 1394-1401.
27. Briat A, Vassaux G. A new transgenic mouse line to image chemically induced p53 activation in vivo. Cancer Sci. 2008; 99: 683-688.
28. Wu JC, Sundaresan G, Iyer M, Gambhir SS. Noninvasive optical imaging of firefly luciferase reporter gene expression in skeletal muscles of living mice. Mol. Ther. 2001; 4: 297-306.
29. Contag PR, Olomu IN, Stevenson DK, Contag CH. Bioluminescent indicators in living mammals. Nat. Med. 1998; 4: 245-247.
30. Niwa H, Yamamura K, Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 1991; 108: 193-199.
31. Toyoshima M, Tanaka N, Aoki J, et al. Inhibition of tumor growth and metastasis by depletion of vesicular sorting protein Hrs: its regulatory role on E-cadherin and beta-catenin. Cancer Res. 2007; 67: 5162-5171.
32. Malaguarnera L, Ferlito L, Di Mauro S, et al. Immunosenescence and cancer: a review. Arch. Gerontol. Geriatr. 2001; 32: 77-93.
33. Connolly DC, Bao R, Nikitin AY, et al. Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Res. 2003; 63: 1389-1397.
34. Dinulescu DM, Ince TA, Quade BJ, et al. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat. Med. 2005; 11: 63-70.
35. Godwin AK, Testa JR, Handel LM, et al. Spontaneous transformation of rat ovarian surface epithelial cells: association with cytogenetic changes and implications of repeated ovulation in the etiology of ovarian cancer. J. Natl Cancer Inst. 1992; 84: 592-601.
36. Testa JR, Getts LA, Salazar H, et al. Spontaneous transformation of rat ovarian surface epithelial cells results in well to poorly differentiated tumors with a parallel range of cytogenetic complexity. Cancer Res. 1994; 54: 2778-2784.
37. Chatzistamou I, Schally AV, Pafiti A, Kiaris H, Koutselini H. Expression of growth hormone-releasing hormone in human primary endometrial carcinomas. Eur. J. Endocrinol. 2002; 147: 381-386.
38. Tsukagoshi S, Saga Y, Suzuki N, et al. Thymidine phosphorylasemediated angiogenesis regulated by thymidine phosphorylase inhibitor in human ovarian cancer cells in vivo. Int. J. Oncol. 2003; 22: 961-967.
39. Brutkiewicz S, Mendonca M, Stantz K, et al. The expression level of luciferase within tumour cells can alter tumour growth upon in vivo bioluminescence imaging. Luminescence 2007; 22: 221-228.
40. Cannistra SA. Cancer of the ovary. New Engl. J. Med. 2004; 351: 2519-2529.
41. Trope C and Kaern J. Adjuvant chemotherapy for early-stage ovarian cancer: review of the literature. J. Clin. Oncol. 2007; 25: 2909-2920.